&ot&uot
Kate Stern
REFERENCE: O-144
KATE STERN, Royal Women’s Hospital, Melbourne
A potential new way of preserving ovarian function during chemotherapy for cancer could be treatment with an antagonist of gonadotropin-releasing hormone: GnRH. A pilot study from Melbourne looked at 18 young women with cancer or auto immune disease due to receive cyclophosphamide therapy. Sarah Maxwell spoke with Kate Stern and heard more about the study.
KATE STERN, Royal Women’s Hospital, Melbourne
A potential new way of preserving ovarian function during chemotherapy for cancer could be treatment with an antagonist of gonadotropin-releasing hormone: GnRH. A pilot study from Melbourne looked at 18 young women with cancer or auto immune disease due to receive cyclophosphamide therapy. Sarah Maxwell spoke with Kate Stern and heard more about the study.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.